XCancer

Of 18F MEL050 Using PET/CT in Metastatic Melanoma

Description:

The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F MEL050 for finding sites of melanoma.

Sponsor:

Unknown Organization

Phase:

Early Phase 1

Contacts:

Grant McArthur (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT01620749 - Click here to see study on

ClinicalTrials.gov

MEL050

Isotope(s):
Target(s):
  • MC1R
Ligand Class: Small Molecules
Inclusion
  • Male and female patients with histologically confirmed melanoma
  • At least one site of metastatic disease, as demonstrated on the pre-study 18F FDG PET/CT scan performed as part of routine clinical care
Exclusion
  • Patients with urinary incontinence or patients who cannot comfortably hold their urine for more than 90 minutes
  • Patients whose only metastatic lesion is in the Central Nervous System
  • Systemic anti-melanoma therapy within the 2 weeks prior to the pre-study 18F FDG PET/CT scan until after the 18F MEL050 PET/CT scan